Avalo Therapeutics to Participate in Upcoming Investor Conferences
TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET
Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
For media and investor inquiriesChristopher Sullivan, CFO Avalo Therapeutics, Inc. ir@avalotx.com410-803-6793
or
Meru AdvisorsLauren Glaserlglaser@meruadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
MBX Biosciences Submits IND for Once-Monthly Obesity Drug
MBX Biosciences Inc. (NASDAQ:MBX) is one of the best IPO stocks to buy according to Wall Street analysts. On June 16, MBX Biosciences announced the submission of an Investigational New Drug/IND application to the US FDA for MBX 4291. This drug is a long-acting GLP-1/GIP receptor co-agonist prodrug being developed for the treatment of obesity. The company's President and CEO, Kent Hawryluk, stated that MBX 4291 is designed to be a potential once-monthly injectable, which could offer less frequent dosing and improved gastrointestinal tolerability, potentially leading to better patient adherence and increased weight loss. MBX 4291 was created using the company's proprietary Precision Endocrine Peptide/PEP platform. A doctor holding a test tube of the biopharmaceutical company's NicAlert drug product while providing patient care. In preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss as tirzepatide, a weekly GLP-1/GIP co-agonist that is already approved. Furthermore, these preclinical studies showed an extended duration of action for MBX 4291's active component compared to tirzepatide, supporting the potential for once-monthly administration. MBX Biosciences Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company that discovers and develops precision peptide therapies for the treatment of endocrine and metabolic disorders. While we acknowledge the potential of MBX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
New Tesla, Nvidia Funds Offer Leveraged Bets
Leverage Shares by Themes offers single-stock funds tied to popular names like Tesla Inc. and Nvidia Corp. that use options to deliver monthly leverage that matches a stock's declines rather than magnify them. Bloomberg's Vildana Hajric reports. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
3 hours ago
- Business Insider
Guggenheim Remains a Buy on Nexstar Media Group (NXST)
In a report released today, Curry Baker from Guggenheim maintained a Buy rating on Nexstar Media Group, with a price target of $250.00. The company's shares closed today at $207.73. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Baker covers the Communication Services sector, focusing on stocks such as Liberty Media Liberty Formula One, Liberty Media Liberty Formula One, and Live Nation Entertainment. According to TipRanks, Baker has an average return of 12.4% and a 64.17% success rate on recommended stocks. In addition to Guggenheim, Nexstar Media Group also received a Buy from Barrington's Patrick Sholl in a report issued today. However, on August 15, Citi maintained a Hold rating on Nexstar Media Group (NASDAQ: NXST).
